Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

4142 - Association of derived neutrophil-to-lymphocyte ratio (dNLR) with pathological complete response (pCR) after neoadjuvant chemotherapy (CT)

Date

29 Sep 2019

Session

Poster Display session 2

Topics

Tumour Site

Breast Cancer

Presenters

Alberto Ocaña

Citation

Annals of Oncology (2019) 30 (suppl_5): v55-v98. 10.1093/annonc/mdz240

Authors

A. Ocaña1, J.I.L. Chacón2, L. Calvo3, A. Antón4, M. Mansutti5, E. Alba6, A. Lluch7, A. Lahuerta8, G. Bisagni9, B. Bermejo7, V. Semiglazov10, M. Thill11, A. Chan12, S. Morales13, J. Albanell14, J. Herranz15, I. Tusquets Trias Bes16, P. Valagussa17, M. Chiesa18, L. Gianni17

Author affiliations

  • 1 Medical Oncolgoy, Hospital General Universitario de Albacete, 02006 - Albacete/ES
  • 2 Medical Oncolgoy, Hospital Hospital Virgen de la Salud, Toledo,, Toledo/ES
  • 3 Medical Oncolgoy, Complejo Hospitalario Universitario de A Coruňa, A Coruña/ES
  • 4 Medical Oncolgoy, Hospital Universitario Miguel Servet, Zaragoza/ES
  • 5 Oncology, Azienda Sanitaria Universitaria Integrata di Udine - Ospedale Santa Maria della Misericordia, 33100 - Udine/IT
  • 6 Medical Oncolgoy, Hospital Clínico Universitario Virgen de la Victoria, Málaga/ES
  • 7 Medical Oncology Departament., Biomedical Research Institute INCLIVA, Hospital Clínico València, University of Valencia, Valencia/ES
  • 8 Medical Oncology, Fundación Onkologikoa, 20014 - San Sebastián/ES
  • 9 Medical Oncology, Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS, 42100 - Reggio Emilia/IT
  • 10 Medical Oncolgoy, N.N. Petrov National Medical Research Center of Oncology, 197758 - Saint-Petersburg/RU
  • 11 Medical Oncolgoy, Kliniken Markus-Krankenhaus, Agaplesion, 60431 - Frankfurt am Main/DE
  • 12 Medical Oncolgoy, Breast Cancer Research Centre BCRC - WA, 6009 - Nedlands/AU
  • 13 Medical Oncolgoy, Hospital Universitario Arnau de Vilanova de Lleida, Lleida/ES
  • 14 Medical Oncolgoy, University Hospital del Mar, 8003 - Barcelona/ES
  • 15 Statistics, GEICAM Spanish Breast Cancer Group, Madrid/ES
  • 16 Medical Oncology Department, Hospital del Mar, 08003 - Barcelona/ES
  • 17 Medical Oncolgoy, Fondazione Michelangelo, 20133 - Milan/IT
  • 18 Translational Research, GEICAM Spanish Breast Cancer Group, Madrid/ES

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 4142

Background

dNLR is a novel biomarker associated with clinical outcome in solid tumors including early stage breast cancer (BC). Here we report the association of dNLR with pCR in triple-negative (TN) and luminal BC patients (pts) treated with neoadjuvant CT.

Methods

This was a retrospective analysis of two randomized studies (GEICAM/2006-03 - NCT00432172 and ETNA - NCT01822314) involving 821 pts with early stage (>2cm) or locally advanced TN or luminal BC receiving anthracycline/taxane-based CT +/- carboplatin (GEICAM/2006-03) or nab-paclitaxel/paclitaxel followed by anthracycline regimen (ETNA). dNLR was calculated as the ratio of neutrophils and the difference between total leukocytes and neutrophils in peripheral blood before CT (baseline) and at the end of treatment (EOT). Logistic regression analyses were used to explore dNLR association with pCR at the two time points by molecular subtype.

Results

684 and 137 pts were from ETNA and GEICAM/2006-03 study respectively (TN n = 308; Luminal n = 513). In TN subgroup median baseline dNLR was 1.61 [interquartile range (IQR): 1.25-2.04] and at EOT 1.65 (IQR: 0.96-2.22). In luminal BC median baseline dNLR was 1.68 (IQR: 1.22-1.96) and at EOT 1.48 (IQR: 0.86-1.93). No association with pCR was found in luminal BC. Baseline dNLR was associated with pCR in TNBC in univariate analysis (OR: 0.709, CI: 0.5-1.006, p = 0.0406). At EOT significant association of dNLR as continuous variable with pCR was observed in TNBC both in univariate and multivariate analysis (OR: 0.665, CI: 0.501-0.884, p = 0.0034, n = 255 and OR: 0.62, CI: 0.406-0.946, p = 0.0231, n = 228 respectively). Quartiles distribution of EOT dNLR was also associated with pCR in univariate and multivariate analysis (Q1 vs combined Q2/Q3/Q4 group: OR: 0.32, CI: 0.17-0.64, p = 5e-04 and OR: 0.26, CI: 0.1-0.63, p = 0.002 respectively). Also a ROC curve - based optimal cut off method revealed significant association of EOT dNLR with pCR in TNBC (>2.231, OR: 0.43, CI: 0.25-0.74, p = 0.0035).

Conclusions

No association was found between dNLR and pCR in luminal BC. High dNLR levels at baseline and especially EOT seem to be associated with worse clinical outcome in TN tumors after neoadjuvant CT.

Clinical trial identification

GEICAM/2006-03 - NCT00432172: 07 Feb 2007 ETNA - NCT01822314: 02 Abr 2013.

Editorial acknowledgement

Legal entity responsible for the study

GEICAM Spanish Breast Cancer Group.

Funding

Has not received any funding.

Disclosure

M. Mansutti: Advisory / Consultancy: Celgene; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pfizer; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: AstraZeneca. A. Lluch: Research grant / Funding (self), Research grant / Funding (institution): Amgen; Research grant / Funding (self), Research grant / Funding (institution): AstraZeneca; Research grant / Funding (self), Research grant / Funding (institution): Boehringer-Ingelheim; Research grant / Funding (self), Research grant / Funding (institution): GSK; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Pfizer; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Roche/Genentech; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Eisai; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Celgene; Research grant / Funding (self), Research grant / Funding (institution): Pierre-Fabre. M. Thill: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Genomic Health; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Amgen; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Celgene; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Eisai; Honoraria (self): Hexal; Honoraria (self), Travel / Accommodation / Expenses: Medtronic; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Myriad; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: PFM Medical; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: RTI Surgical; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Teva; Advisory / Consultancy, Travel / Accommodation / Expenses: Biom-up; Advisory / Consultancy, Travel / Accommodation / Expenses: Lilly; Advisory / Consultancy, Travel / Accommodation / Expenses: Neodynamics; Advisory / Consultancy, Travel / Accommodation / Expenses: Norgine; Advisory / Consultancy, Travel / Accommodation / Expenses: Tesaro. L. Gianni: Advisory / Consultancy, MetIS, Novartis, Odonate Therapeutics, Revolution Medicine, Synaffix, Zymeworks: CONSULTANCY: ADC Therapeutics,; Advisory / Consultancy, RESEARCH FUNDING (institution): Zymeworks, Daiichi SankyoZymeworks, Daiichi Sankyo: AstraZeneca; Advisory / Consultancy, PATENTS, ROYALTIES: European Patent Application N. 12195182.6 and 12196177.5’, Roche: Celgene; Advisory / Consultancy: Lilly; Advisory / Consultancy: G1 Therapeutics; Advisory / Consultancy: Genentech; Advisory / Consultancy: Genomic Health; Advisory / Consultancy: MSD; Advisory / Consultancy: Oncolytics Biotech; Advisory / Consultancy: Odonate Therapeutics; Advisory / Consultancy: Onkaido; Advisory / Consultancy: Roche; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Tahio Pharmaceutical; Advisory / Consultancy: Sandoz; Advisory / Consultancy: SeaGen,; Advisory / Consultancy: Synthon; Advisory / Consultancy: Zymeworks,; Advisory / Consultancy: CD47; Advisory / Consultancy: GENENTA. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.